Investors & Media

Press Releases


 
Press Releases
  Date Title View
Apr 25, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, May 9, 2017 at 4:30 ...
Apr 24, 2017
Key additions and promotions to team in commercial, development and regulatory roles CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorde...
Apr 19, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone (SAGE-547) and SAGE-217 at the American Academy of ...
Apr 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on April 3, 2017, the Compensation Committee of Sage's Board of Directors granted non-...
Mar 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation Committee of Sage's Board of Directors granted non-...
Feb 23, 2017
Continued momentum expected in 2017 with several programs anticipating clinical trial results this year, including two Phase 3 programs Phase 2 placebo-controlled study of SAGE-217 in major depressive disorder expected to begin in 1H 2017 First NMDA candidate, SAGE-718, pl...
Feb 17, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, February 23, 2017 ...
Feb 16, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD). During the course of the interview, Dr. Jonas acknowledged the industry's interest in the MDD data. Dr. Jonas' ...
Feb 13, 2017
Open-label Pilot Study of Once Daily, Orally Administered Molecule Demonstrates Positive Signal of Activity and Tolerability CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat lif...
Feb 7, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will participate in the following upcoming conferences: ...
FirstPrevious
2
... NextLast
= add release to Briefcase